<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81847">
  <stage>Registered</stage>
  <submitdate>9/02/2007</submitdate>
  <approvaldate>14/02/2007</approvaldate>
  <actrnumber>ACTRN12607000128493</actrnumber>
  <trial_identification>
    <studytitle>The effect of low dose fluoride on bone</studytitle>
    <scientifictitle>A randomized, double-blind, placebo-controlled, dose-finding study of the effects of sodium fluoride on bone turnover, bone density and bone histology in osteopenic post menopausal women.</scientifictitle>
    <utrn />
    <trialacronym>FEAST</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects randomized to placebo or 1 of 3 treatment groups: sodium fluoride 2.5mg daily, per oral, 5mg daily per oral, 10mg daily per oral, for 1 year. No dosage increments Active and placebo tablets are identical in appearance</interventions>
    <comparator>Matching placebo, per oral for 1 year</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in lumbar spine bone mineral density (BMD</outcome>
      <timepoint>At 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in hip BMD </outcome>
      <timepoint>At 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in forearm BMD</outcome>
      <timepoint>At 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in biochemical markers of bone turnover </outcome>
      <timepoint>At 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bone histology </outcome>
      <timepoint>At 1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Postmenopausal 5 yrs or more (menopause defined as at least 12 months since last period in woman aged &gt; 45 yrs with intact uterus, or serum follicle stimluating hormone (FSH) &gt; 50 IU/l in younger or hysterectomized woman)- Bone density T score less than -1.0 and greater than -2.5 at L1-L4 or Total Hip.- BMD T-score &lt;-2.5 at lumbar spine or total hip, but participant is not a suitable candidate for, or has decided against taking, osteoporosis therapy</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Medical Conditions- renal impairment (serum creatinine 120 Âµmol/L).- congestive heart failure- chronic liver disease.- untreated hypothyroidism or hyperthyroidism.- concurrent major systemic illness, including malignancy.- active major gastrointestinal disease.- metabolic bone diseases, or serum alkaline phosphatase (ALP) &gt; 2x normal limit.- primary hyperparathyroidism. - Vitamin D insufficiency (25 hydroxyvitamin D [OHD] &lt; 50nmol/L)Medications- use of oral glucocorticoid drugs equivalent to an average dose of prednisone 2.5 mg/day in the preceding 12 months- use of aminobisphosphonates within the past 2 years, or etidronate within the past 1 year- use of hormone replacement therapy within the last 12 months- use of other medication known to cause osteoporosis or interfere with bone metabolism.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Staff member enrolling subject unaware of treatment allocation, allocation concealment by central randomization</concealment>
    <sequence>Sequence generation by computer-generated random numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>subjects and assessors are blinded</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate>30/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/03/2010</actualenddate>
    <samplesize>180</samplesize>
    <actualsamplesize>180</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Associate Professor Andrew Grey</primarysponsorname>
    <primarysponsoraddress>Department of Medicine
University of Auckland
Private Bag 92019
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541
Wellesley St.,
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Auckland Medical research Foundation</fundingname>
      <fundingaddress>PO Box 110 139
Auckland 1148</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Auckland</sponsorname>
      <sponsoraddress>Private Bag 92019
Auckland</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a 1 year study designed to investigate the effects of low-dose fluoride therapy on bone. We are testing whether doses of fluoride that are lower than have been studied in previous trials might have positive effects on bone density and metabolism, without affecting bone quality. 180 postmenopausal women with mild bone thinning will be randomly (by chance) allocated to receive placebo (inactive) treatment or one of 3 low doses of fluoride (2.5, 5 or 10 mg/day). Each participant will be seen on 5 occasions during the study, for assessment of bone density and bone-related biochemistry (blood and urine tests). Bone biopsy from the back of the pelvis will be sought from 6-10 participants in each treatment group at the end of the study - this is a voluntary procedure.</summary>
    <trialwebsite />
    <publication>Grey A, Garg S, Dray M, Purvis L, Horne A, Callon K, Gamble G, Bolland M, Reid IR, Cundy T. Low dose fluoride in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2013;98:2301-2307</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland-Northern X Regional Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/01/2007</ethicapprovaldate>
      <hrec> NTX/06/12/152</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Associate Professor Andrew Grey</name>
      <address>Department of Medicine,
University of Auckland,
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax />
      <email>a.grey@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Associate Professor Andrew Grey</name>
      <address>Department of Medicine,
University of Auckland,
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax />
      <email>a.grey@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Andrew Grey</name>
      <address>Department of Medicine
university of Auckland
Private Bag 92019
Auckland
New Zealand</address>
      <phone>+6493737599</phone>
      <fax />
      <email>a.grey@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>